U.S. Senators Jerry Moran R-Kan. and Tina Smith D-Minn. reintroduced the Cancer Drug Parity Act to bring down healthcare costs for cancer patients by making certain insurance companies cover orally administered cancer drugs in the same way as traditional intravenous IV chemotherapy.As the number of orally administered cancer drugs increase each year patients ought to be able to immediately benefit from these medical advancements said Sen. Moran. This sensible legislation would keep health insurance on pace with the latest cancer treatments build on laws already implemented in 43 states and expand access to orally administered cancer drugs for 100 million individuals covered through group and individual health plans. I am a strong supporter of medical research to find new treatments therapies and cures and I will work to make certain these cutting-edge treatments can reach cancer patients and ultimately save lives.Advances in cancer treatment have made it possible for Americans to get life-saving oral cancer medication. This means people can now take the life-saving medicine they need without having to leave their homes and in a far less intrusive way than traditional IV chemotherapy said Sen. Smith. But since oral cancer medications are self-administered many people are having to shell out more dollars because this medication isnt covered the same way as IV treatments. Im reintroducing my bipartisan bill with Senator Jerry Moran of Kansas to put a stop to charging more for oral cancer drugs because we should be doing all we can to make life-saving cancer treatment more affordable for all Americans.Science is dramatically changing the way cancer is treated. Even with these breakthroughs too many cancer patients cant access their treatments because insurance rules have not kept pace with innovation said Louis J. DeGennaro Ph.D. President and CEO of The Leukemia Lymphoma Society. The Cancer Drug Parity Act will eliminate the financial barriers that stand between many cancer patients and the breakthrough treatments that could save their lives. The Leukemia Lymphoma Society applauds Senator Smith and Senator Moran for their leadership on behalf of cancer patients and stands ready to work with Congress to move this important bill forward.Currently over 40 states including Kansas and Minnesota and the District of Columbia have passed oral parity laws that stop insurers from charging more for prescribed orally administered cancer medicine than traditional IV chemotherapy. The Cancer Drug Parity Act would build on this work by expanding these protections at the federal level.The Cancer Drug Parity Act would prevent insurers from covering oral and self-administered medicines at different cost sharing rates than traditional IV chemotherapy. It would not mandate that healthcare plans provide chemotherapy coverage but rather only apply to plans already covering chemotherapy.This bipartisan legislation is cosponsored by U.S. Senators Chris Murphy D-Conn. and Roger Wicker R-Miss..The Cancer Drug Parity Act has broad support from a number of organizations including AIM at Melanoma American Cancer Society Cancer Action Network American Society of Clinical Oncology American Society of Hematology Aplastic Anemia and MDS International Foundation Association of Community Cancer Centers Association of American Cancer Institutes Astellas Pharma US CancerCare Cancer Support Community Celgene Community Oncology Alliance Dana-Farber Cancer Institute Debbies Dream Foundation Curing Stomach Cancer Facing Our Risk of Cancer Empowered FORCE Fight Colorectal Cancer Genentech Inc. HematologyOncology Pharmacy Association International Myeloma Foundation Karmanos Cancer Institute Leukemia Lymphoma Society LUNGevity Lymphoma Research Foundation Millennium The Takeda Oncology Co. Medical College of Wisconsin National Brain Tumor Society National Patient Advocate Foundation Oncology Nursing Society Ovarian Cancer Research Alliance Patient Services Incorporated Roswell Park Comprehensive Cancer Center Susan G. Komen The Ohio State University Comprehensive Cancer Center-James Cancer Hospital and Richard J Solove Institute WVU Medicine and Zero The End of Prostate Cancer.
🔍 Key Information
📄
Tender Reference No.
442839046
📅
Publication Date
13 Mar 2019
🌐
Sector
Banking, Finance, Insurance and Securities (BFIS)
📝
Notice Type
News
📍
Location
United states
📁
Documents & Downloads
No documents found
🏷️ CPV
No CPV found
Need help with this bid?
Our bid experts can help you find, evaluate & win more tenders.